The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Anish Patel discussing 90-day urologic complications from pelvic ...
Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer. November 7, 2024 DNA Damage Response Alterations Predict for Neoadjuvant ...
The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation ...
This case study describes the clinical, medical and administrative management of kidney cancer secondary to occupational exposure to trichloroethylene, a chlorinated solvent classified as a known ...
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease categorized as low, intermediate, high, or very high risk, for which recurrence and progression rates and thus management ...
As treatments for bladder cancer (BC) become more targeted and specific, understanding the molecular underpinnings and subtypes becomes increasingly important. Technological advancements such as ...
Background For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1L) systemic treatment for improved outcomes.
Acinar adenocarcinoma represents the dominant histological type of prostate cancer. 1,2 Conversely, non-epithelial malignancies are extremely rare tumor entities with unfavorable survival outcomes.
(UroToday.com) The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Dr. Peter Sullivan discussing financial toxicity in ...